Hsp40 Gene Therapy Exerts Therapeutic Effects on Polyglutamine Disease Mice via a Non-Cell Autonomous Mechanism

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Popiel, H Akiko ^a   Takeuchi, Toshihide ^a   Fujita, Hiromi ^a   Yamamoto, Kazuhiro ^a   Ito, Chiyomi ^b   Yamane, Hiroshi ^a   Muramatsu, Shin ichi ^c   Toda, Tatsushi ^b   Wada, Keiji ^a   Nagai, Yoshitaka ^a,d  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN 40; PARVOVIRUS VECTOR; POLYGLUTAMINE; POLYGLUTAMINE BINDING PEPTIDE 1; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; LIFESPAN; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NONHUMAN; PROTEIN SECRETION; VIRAL GENE THERAPY;

ANIMALS; BRAIN; CELLS, CULTURED; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HAND STRENGTH; HSP40 HEAT-SHOCK PROTEINS; HUNTINGTON DISEASE; INCLUSION BODIES; LONGEVITY; MICE; MOTOR ACTIVITY; NEURONS; OLIGOPEPTIDES; PEPTIDES; PHENOTYPE; WEIGHT LOSS;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

EID: 84870581997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051069     Document Type: Article

References (44)

1. Gusella JF, MacDonald ME, (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 1: 109-115.
2. Orr HT, Zoghbi HY, (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30: 575-621.
3. Michalik A, Van Broeckhoven C, (2003) Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 12 Spec No 2: R173-186.
4. Shao J, Diamond MI, (2007) Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 16 Spec No. 2: R115-123.
5. Nagai Y, Popiel HA, (2008) Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed β-sheet hypothesis. Curr Pharm Des 14: 3267-3279.
6. Williams AJ, Paulson HL, (2008) Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci 31: 521-528.
7. Bauer PO, Nukina N, (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 110: 1737-1765.
8. Aguzzi A, Rajendran L, (2009) The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 64: 783-790.
9. Brundin P, Melki R, Kopito R, (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11: 301-307.
10. Lee SJ, Desplats P, Sigurdson C, Tsigelny I, Masliah E, (2010) Cell-to-cell transmission of non-prion protein aggregates. Nat Rev Neurol 6: 702-706.
11. Frost B, Diamond MI, (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11: 155-159.
12. Bates G, (2003) Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361: 1642-1644.
13. Herbst M, Wanker EE, (2006) Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation. Curr Pharm Des 12: 2543-2555.
14. Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, et al. (2000) Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J Biol Chem 275: 10437-10442.
15. Nagai Y, Inui T, Popiel HA, Fujikake N, Hasegawa K, et al. (2007) A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 14: 332-340.
16. Popiel HA, Burke JR, Strittmatter WJ, Oishi S, Fujii N, et al. (2011) The aggregation inhibitor peptide QBP1 as a therapeutic molecule for the polyglutamine neurodegenerative diseases. J Amino Acids 2011: 265084.
17. Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, et al. (2003) Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum Mol Genet 12: 1253-1259.
18. Liberek K, Lewandowska A, Zietkiewicz S, (2008) Chaperones in control of protein disaggregation. EMBO J 27: 328-335.
19. Kampinga HH, Craig EA, (2010) The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol 11: 579-592.
20. Hartl FU, Bracher A, Hayer-Hartl M, (2011) Molecular chaperones in protein folding and proteostasis. Nature 475: 324-332.
21. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, et al. (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23: 425-428.
22. Kazemi-Esfarjani P, Benzer S, (2000) Genetic suppression of polyglutamine toxicity in Drosophila. Science 287: 1837-1840.
23. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, et al. (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408: 101-106.
24. Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM, (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9: 2811-2820.
25. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, et al. (2000) Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci USA 97: 5750-5755.
26. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, et al. (2001) Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10: 1511-1518.
27. Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, et al. (2003) Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 23: 2203-2211.
28. Hansson O, Nylandsted J, Castilho RF, Leist M, Jaattela M, et al. (2003) Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Brain Res 970: 47-57.
29. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, et al. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13: 1389-1405.
30. Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, et al. (2012) Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain.
31. Okada T, Nomoto T, Shimazaki K, Lijun W, Lu Y, et al. (2002) Adeno-associated virus vectors for gene transfer to the brain. Methods 28: 237-247.
32. Davidson BL, Breakefield XO, (2003) Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 4: 353-364.
33. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
34. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, et al. (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91: 2076-2080.
35. Hageman J, Rujano MA, van Waarde MA, Kakkar V, Dirks RP, et al. (2010) A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell 37: 355-369.
36. Ross CA, Poirier MA, (2005) Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 6: 891-898.
37. Howarth JL, Kelly S, Keasey MP, Glover CP, Lee YB, et al. (2007) Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther 15: 1100-1105.
38. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, et al. (2010) A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18: 1731-1735.
39. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, et al. (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 11: 219-225.
40. Herrera F, Tenreiro S, Miller-Fleming L, Outeiro TF, (2011) Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr 3: RRN1210.
41. Goodenough DA, Paul DL, (2009) Gap junctions. Cold Spring Harb Perspect Biol 1: a002576.
42. Calderwood SK, Mambula SS, Gray PJ Jr, Theriault JR, (2007) Extracellular heat shock proteins in cell signaling. FEBS Lett 581: 3689-3694.
43. Bauer PO, Goswami A, Wong HK, Okuno M, Kurosawa M, et al. (2010) Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol 28: 256-263.
44. Ohtsuka K, (1993) Cloning of a cDNA for heat-shock protein hsp40, a human homologue of bacterial DnaJ. Biochem Biophys Res Commun 197: 235-240.